局部晚期宫颈癌放化疗联合磁共振图像引导近距离放疗后局部失败的危险因素:EMBRACE-I研究结果
多因素分析显示组织学类型、CTVHR D90、肿瘤最大径、CTVHR>45 cm³、总治疗时间、诊断时MRI肿瘤坏死、诊断时及MR-IGABT时宫体浸润、MR-IGABT时直肠系膜浸润显著影响局部失败。剂量反应分析显示CTVHR D90达85 Gy时鳞癌3年局部控制率95%(95%CI 94-97),腺癌/腺鳞癌为86%(95%CI 81-90)。
要点
- 98例局部失败中90%位于MR-IGABT靶体积内。
- CTVHR D90 85 Gy时鳞癌3年局部控制率95%,腺癌/腺鳞癌86%。
核心结论
- 本研究证实GYN GEC-ESTRO/ICRU-89靶区概念的安全性和有效性,并为MR-IGABT的剂量处方和局部失败新危险因素提供大规模证据。
主要发现
- 81例患者治疗结束后3个月存在持续病灶,其中60例在6-9个月时未经进一步治疗达到局部控制,21例出现进展。
- 77例患者在完全缓解后出现局部复发,共计98例局部失败,其中90%位于MR-IGABT靶体积内。
- 多因素分析显示组织学类型、CTVHR D90、肿瘤最大径、CTVHR>45 cm³、总治疗时间、诊断时MRI肿瘤坏死、诊断时及MR-IGABT时宫体浸润、MR-IGABT时直肠系膜浸润对局部失败有显著影响。
- 剂量反应分析显示CTVHR D90为85 Gy时,鳞癌3年局部控制率为95%(95%CI 94-97),腺癌/腺鳞癌为86%(95%CI 81-90)。
关键数值与推荐
- CTVHR D90 85 Gy时鳞癌3年局部控制率95%(95%CI 94-97),腺癌/腺鳞癌86%(95%CI 81-90)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report clinical and treatment characteristics, remission and failure patterns, and risk factors for local failure (LF) from the EMBRACE-I study. MATERIALS AND METHODS: EMBRACE-I was a prospective, observational, multicenter cohort study on magnetic resonance imaging-based image-guided adaptive brachytherapy (MR-IGABT) in locally advanced cervical cancer. Treatment consisted of external beam radiotherapy, concurrent chemotherapy, and MR-IGABT. LF was defined as progressive or recurrent disease in the cervix, uterus, parametria, pelvic wall, or vagina. Competing risk analysis was used to estimate local tumor control (LC) and Cox proportional regression models for multivariable analysis and dose-response analysis. RESULTS: One thousand three hundred eighteen patients with a median follow-up of 52 months were available for this analysis. Eighty-one patients had persistent disease 3 months after end of treatment. Of those, 60 patients achieved LC at 6-9 months without further treatment, whereas 21 patients had progressive disease. In addition, 77 patients developed a local recurrence after complete remission comprising a total number of 98 LFs. LFs were located inside the MR-IGABT target volumes in 90% of patients with LF. In multivariable analysis, histology, minimal dose to 90% of high-risk clinical target volume (CTVHR), maximum tumor dimension, CTVHR > 45 cm3, overall treatment time, tumor necrosis on magnetic resonance imaging at diagnosis, uterine corpus infiltration at diagnosis and at MR-IGABT, and mesorectal infiltration at MR-IGABT had significant impact on LF. Dose-response analysis showed that a minimal dose to 90% of 85 Gy to the CTVHR led to 95% (95% CI, 94 to 97) LC 3 years postintervention for squamous cell in comparison to 86% (95% CI, 81 to 90) for adeno/adenosquamous carcinoma histology. CONCLUSION: The present study demonstrates the safety and validity of the GYN GEC-ESTRO/ICRU-89 target concept and provides large-scale evidence for dose prescription and new risk factors for LF in MR-IGABT in locally advanced cervical cancer.
引用
- Schmid MP, Lindegaard JC, Mahantshetty U, et al. Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study. J Clin Oncol. 2023. PMID: 36599120. doi:10.1200/JCO.22.01096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。